FTC Requires J&J (JNJ) to Sell DVR System for Wrist Fractures to Biomet -Bloomberg
Tweet Send to a FriendGet Alerts JNJ Hot Sheet
Price: $86.82 -0.45%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 3%
Revenue Growth %: +8.7%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 3%
Revenue Growth %: +8.7%
Trade JNJ Now!
Related to J&J's (NYSE: JNJ) proposed Synthese deal, the FTC has required the company to sell its DVR system for surgical treatment of wrist fractures to Biomet.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Bausch & Lomb near deal to sell to Valeant Pharmaceuticals (VRX) - WSJ
- Saks (SKS) said to hire Goldman Sachs for a sale - NY Post
- China Approves Acquisition of Heinz (HNZ) by Berkshire Hathaway and 3G Capital
Create E-mail Alert Related Categories
Mergers and Acquisitions, Rumors
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
